GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (NAS:LIXT) » Definitions » E10

Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) E10 : $-3.79 (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Lixte Biotechnology Holdings E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Lixte Biotechnology Holdings's adjusted earnings per share data for the three months ended in Mar. 2024 was $-0.430. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-3.79 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was -2.60% per year. During the past 5 years, the average E10 Growth Rate was -1.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Lixte Biotechnology Holdings was 2.40% per year. The lowest was -2.70% per year. And the median was -0.55% per year.

As of today (2024-06-05), Lixte Biotechnology Holdings's current stock price is $2.52. Lixte Biotechnology Holdings's E10 for the quarter that ended in Mar. 2024 was $-3.79. Lixte Biotechnology Holdings's Shiller PE Ratio of today is .


Lixte Biotechnology Holdings E10 Historical Data

The historical data trend for Lixte Biotechnology Holdings's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings E10 Chart

Lixte Biotechnology Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.52 -3.56 -3.89 -3.75 -3.84

Lixte Biotechnology Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.82 -3.88 -3.89 -3.84 -3.79

Competitive Comparison of Lixte Biotechnology Holdings's E10

For the Biotechnology subindustry, Lixte Biotechnology Holdings's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lixte Biotechnology Holdings's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lixte Biotechnology Holdings's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Lixte Biotechnology Holdings's Shiller PE Ratio falls into.



Lixte Biotechnology Holdings E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lixte Biotechnology Holdings's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.43/131.7762*131.7762
=-0.430

Current CPI (Mar. 2024) = 131.7762.

Lixte Biotechnology Holdings Quarterly Data

per share eps CPI Adj_EPS
201406 -1.200 100.560 -1.573
201409 -0.600 100.428 -0.787
201412 -0.600 99.070 -0.798
201503 -1.200 99.621 -1.587
201506 -0.600 100.684 -0.785
201509 -1.200 100.392 -1.575
201512 -0.600 99.792 -0.792
201603 -0.600 100.470 -0.787
201606 -0.600 101.688 -0.778
201609 -0.600 101.861 -0.776
201612 -0.600 101.863 -0.776
201703 -0.600 102.862 -0.769
201706 -0.600 103.349 -0.765
201709 -0.600 104.136 -0.759
201712 -0.600 104.011 -0.760
201803 -0.600 105.290 -0.751
201806 -0.600 106.317 -0.744
201809 -1.200 106.507 -1.485
201812 -0.600 105.998 -0.746
201903 -0.600 107.251 -0.737
201906 -0.600 108.070 -0.732
201909 -1.200 108.329 -1.460
201912 -0.400 108.420 -0.486
202003 -0.300 108.902 -0.363
202006 -0.300 108.767 -0.363
202009 -1.400 109.815 -1.680
202012 -0.800 109.897 -0.959
202103 -1.400 111.754 -1.651
202106 -1.300 114.631 -1.494
202109 -0.900 115.734 -1.025
202112 -1.500 117.630 -1.680
202203 -1.200 121.301 -1.304
202206 -0.950 125.017 -1.001
202209 -0.890 125.227 -0.937
202212 -0.980 125.222 -1.031
202303 -0.820 127.348 -0.849
202306 -1.000 128.729 -1.024
202309 -0.490 129.860 -0.497
202312 -0.410 129.419 -0.417
202403 -0.430 131.776 -0.430

Add all the adjusted EPS together and divide 10 will get our e10.


Lixte Biotechnology Holdings  (NAS:LIXT) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Lixte Biotechnology Holdings E10 Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) Business Description

Traded in Other Exchanges
N/A
Address
680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101
Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.
Executives
Rene Bernards director KONINGSVAREN 37, ABCOUDE P7 1391AD
Van Der Baan Bastiaan Jeroen director HOGEWEG 4-H, AMSTERDAM P7 1098CB
Eric Forman 10 percent owner 117 E. 29TH ST., APT. 5A, NEW YORK NY 10016
Regina Brown director 248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733
Glenn Krinsky 10 percent owner C/O SRKP 1, INC., 1900 AVENUE OF THE STARS, SUITE 310, LOS ANGELES CA 90067
Yun Yen director 1301 OAKLAWN ROAD, ARCADIA CA 91006
Robert Greenberg 10 percent owner SKECHERS USA INC, 228 MANHATTAN BEACH BLVD, MANHATTAN BEACH CA 90266
Gil Schwartzberg 10 percent owner 269 S. BEVERLY DR., #1315, BEVERLY HILLS CA 90212
Philip F Palmedo director 1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067
John S Kovach director, 10 percent owner, officer: Pres., CFO & Secty 1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067
Stephen J. Forman director 248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733
Hung Tak Ho 10 percent owner MAYFAIR BY THE SEA II, TOWER T8, 1/F, UNIT A, 21 FO CHUN ROAD, PAK SHEK KOK, TAIPO K3 00000
Robert N Weingarten officer: Vice President and CFO 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367
James Miser officer: Chief Medical Officer 680 E COLORADO BLVD., SUITE 180, PASADENA CA 91101
Jane Merrill Riggs 10 percent owner 4852 SAINT ANDRES AVENUE, LA VERNE CA 91750

Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) Headlines

From GuruFocus